XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-based compensation (Tables)
6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Assumptions used to estimate fair value of stock options granted  
The assumptions used to estimate the fair value of stock options granted during the years ended December 31, 2021 and 2020 are as follows:
 
    
Years ended
December 31,
 
    
2021
    
2020
 
Expected dividend yield
     0%        0%  
Expected volatility
     56%        45%  
Expected term (years)
     8.53        9.41  
Risk-free interest rate
     0.87%        0.43%  
Stock option activity  
The following table summarizes the Company’s stock option activity during the periods presented (in thousands except share and per share data):
 
    
Number of
options
outstanding
    
Weighted
average
exercise
price ($)
    
Weighted
average
remaining
contractual
term
(years)
    
Aggregate
intrinsic
value ($)
 
Balance as of December 31, 2020
     12,654,807        0.81        9.38        —    
D-Wave
options granted
     4,369,866        0.82        —          —    
D-Wave
options exercised
     (105,203      0.81        —          —    
D-Wave
options forfeited
     (171,204      0.81        —          —    
D-Wave
options expired
     (412,132      0.81        —          —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Balance as of December 31, 2021
     16,336,134        0.81        8.55        80,179  
    
 
 
    
 
 
    
 
 
    
 
 
 
Options unvested as of December 31, 2021
     6,943,273        0.81        8.53        77,423  
    
 
 
    
 
 
    
 
 
    
 
 
 
Options exercisable as of December 31, 2021
     9,392,861        0.81        8.20        46,116  
    
 
 
    
 
 
    
 
 
    
 
 
 
Preferred stock warrants outstanding and exercisable  
As
of December 31, 2021, the following United States dollar common stock warrants were outstanding and exercisable:
 
    
Number of
warrants
outstanding
    
Weighted
average
exercise
price ($)
    
Expiry Date
    
Number
exercisable
 
       617,972      $ 1.75       
14-April-22
       617,972  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total, December 31, 2021
     617,972      $ 1.75                 617,972  
    
 
 
    
 
 
    
 
 
    
 
 
 
As of December 31, 2021, the following United States dollar preferred stock warrants were outstanding and exercisable:
 
    
Number of
warrants
outstanding
    
Weighted
average
exercise
price ($)
    
Expiry Date
    
Number
exercisable
 
       3,247,637      $ 1.92       
29-Nov-26
       1,299,055  
    
 
 
    
 
 
    
 
 
    
 
 
 
Total, December 31, 2021
     3,247,637      $ 1.92                 1,299,055  
    
 
 
    
 
 
    
 
 
    
 
 
 
Stock-based compensation expense  
The following table summarizes the stock-based compensation expense classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):
 
    
Years ended
December 31,
 
    
2021
    
2020
 
Research and development
   $ 338      $ 1,513  
General and administrative
     1,164        1,346  
Sales and marketing
     237        130  
    
 
 
    
 
 
 
Total stock-based compensation
   $ 1,739      $ 2,989  
    
 
 
    
 
 
 
Common stock and preferred stock warrant [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Stock option activity  
A continuity of the Company’s United States dollar common stock warrants issued and outstanding is as follows:
 
    
Number
of
common
stock
warrants
    
Weighted
average
exercise
price ($)
    
Number of
preferred
stock
warrants
    
Weighted
average
exercise
price ($)
 
Balance as of December 31, 2020
     617,972        1.75        3,247,637        1.92  
    
 
 
    
 
 
    
 
 
    
 
 
 
Granted during the period
     —          —          —          —    
Expired during the period
     —          —          —          —    
Exercised during the period
     —          —          —          —    
    
 
 
    
 
 
    
 
 
    
 
 
 
Balance as of December 31, 2021
     617,972        1.75        3,247,637        1.92  
    
 
 
    
 
 
    
 
 
    
 
 
 
DWave System [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Assumptions used to estimate fair value of stock options granted
There were no options granted during the six months ended June 30, 2022. The assumptions used to estimate the fair value of stock options granted during the six months ended June 30, 2021 are as follows:
 
 
  
Six months ended
June 30,
 
 
  
    2022    
 
  
    2021    
 
Expected dividend yield
     —          0
Expected volatility
     —          50
Expected term (years)
     —          6.08  
Risk-free interest rate
     —          0.83
 
Stock option activity
The following table summarizes the Company’s stock option activity during the periods presented (in thousands except share and per share data):
 
 
  
Number of
options
outstanding
 
  
Weighted
average
exercise
price ($)
 
  
Weighted
average
remaining
contractual term
(years)
 
  
Aggregate
intrinsic
value ($)
 
Balance as of December 31, 2021
     16,336,134        0.81        8.55        80,179  
Granted
     —                             
Exercised
     (174,378      0.81                    
Forfeited
     (840,002      0.81                    
Expired
     (11,077      0.81                    
    
 
 
    
 
 
    
 
 
    
 
 
 
Balance as of June 30, 2022
     15,310,677        0.81        7.96        75,144  
    
 
 
    
 
 
    
 
 
    
 
 
 
Unvested as of June 30, 2022
     4,698,271        0.81        7.77        73,479  
    
 
 
    
 
 
    
 
 
    
 
 
 
Exercisable as of June 30, 2022
     10,612,406        0.81        7.43        52,098  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
Preferred stock warrants outstanding and exercisable
As of June 30, 2022, the following United States dollar preferred stock warrants were outstanding and exercisable:
 
 
  
Number of
warrants
outstanding
 
  
Weighted
average
exercise
price ($)
 
  
Expiry Date
 
  
Number
exercisable
 
       3,247,637      $ 1.92       
29-Nov-26
       1,299,055  
    
 
 
    
 
 
             
 
 
 
Total, June 30, 2022
     3,247,637      $ 1.92                 1,299,055  
    
 
 
    
 
 
             
 
 
 
 
Stock-based compensation expense
The following table summarizes the stock-based compensation expense classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):
 

 
  
Three months ended
June 30,
 
 
  
2022
 
  
2021
 
Research and development
   $ 117      $ 58  
General and administrative
     641        74  
Sales and marketing
     58        37  
    
 
 
    
 
 
 
Total stock-based compensation
   $ 816      $ 169  
    
 
 
    
 
 
 
 
    
Six months ended
June 30,
 
    
2022
    
2021
 
Research and development
   $ 210      $ 88  
General and administrative
     1,270        173  
Sales and marketing
     120        69  
    
 
 
    
 
 
 
Total stock-based compensation
   $ 1,600      $ 330